Insider Selling: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells 1,234 Shares of Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali sold 1,234 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $25.11, for a total value of $30,985.74. Following the completion of the sale, the chief financial officer now owns 37,163 shares of the company’s stock, valued at approximately $933,162.93. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Asif Ali also recently made the following trade(s):

• On Friday, March 1st, Asif Ali sold 14,248 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $32.24, for a total value of $459,355.52.

Protagonist Therapeutics Stock Up 1.5 %

PTGX stock traded up $0.39 during midday trading on Friday, reaching $25.61. 452,280 shares of the company’s stock traded hands, compared to its average volume of 711,234. The company has a 50-day simple moving average of $28.52 and a two-hundred day simple moving average of $22.91. Protagonist Therapeutics, Inc. has a 1-year low of $13.72 and a 1-year high of $33.34. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -17.19 and a beta of 2.01.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.39. The business had revenue of $60.00 million for the quarter, compared to analyst estimates of $60.00 million. Equities research analysts forecast that Protagonist Therapeutics, Inc. will post 1.18 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on PTGX shares. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of Protagonist Therapeutics in a research report on Wednesday, February 28th. JPMorgan Chase & Co. raised their target price on Protagonist Therapeutics from $34.00 to $37.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 28th. Finally, StockNews.com upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $36.00.

Institutional Investors Weigh In On Protagonist Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its stake in shares of Protagonist Therapeutics by 96.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,473 shares of the company’s stock valued at $25,000 after buying an additional 723 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Protagonist Therapeutics in the 2nd quarter valued at $76,000. Tower Research Capital LLC TRC increased its stake in shares of Protagonist Therapeutics by 88.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,118 shares of the company’s stock valued at $86,000 after buying an additional 1,460 shares during the period. Jane Street Group LLC increased its stake in shares of Protagonist Therapeutics by 273.3% in the 3rd quarter. Jane Street Group LLC now owns 10,289 shares of the company’s stock valued at $87,000 after buying an additional 7,533 shares during the period. Finally, Virtus ETF Advisers LLC increased its stake in shares of Protagonist Therapeutics by 29.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,457 shares of the company’s stock valued at $102,000 after buying an additional 1,017 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.